Biopharmaceutical Manufacturing, Upstream, Downstream …
4 days ago · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
About us - biopharma-reporter.com
About Biopharma Reporter. Biopharma Reporter is an essential resource for the biopharma industry, covering large molecules (biologics). We focus on the key trends shaping this dynamic sector, including contract research organizations, patient-centric innovations, AI-driven data management, and the rapidly evolving landscape of cell and gene therapies.
Aditum Bio and Leads Biolabs join forces to fight autoimmune …
Nov 7, 2024 · The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new company that will develop a potentially first-in-class tri-specific T cell engager for the treatment of difficult-to-treat autoimmune diseases.
Ottimo Pharma emerges from stealth mode with promising cancer …
Oct 29, 2024 · UK-based private biotech company Ottimo Pharma has emerged from stealth mode after four years with the appointment of a strong leadership team.
Phase 1 clinical trials using program APTN-101 to target …
Sep 10, 2024 · US biotech company Adaptin Bio has emerged from stealth with the announcement that the FDA has cleared an Investigational New Drug application (IND) for its program APTN-101, a therapy targeting glioblastoma, also known as WHO classified grade 4 malignant glioma.
Positive results for Ionis Pharmaceuticals antisense therapy
Jul 23, 2024 · An open label phase 1/2 trial of Ionis’s antisense oligonucleotide therapy in 51 patients with the rare genetic condition Angelman syndrome resulted in 97% of those given a medium or high dose of the therapy achieving significant symptom improvement measured by a clinical score known as the Symptoms of Angelman …
Benefits of registering
Stay one step ahead. Biopharma Reporter is an essential resource for the biopharma industry, covering large molecules (biologics). We focus on the key trends shaping this dynamic sector, including contract research organizations, patient-centric innovations, AI-driven data management, and the rapidly evolving landscape of cell and gene therapies.
AbbVie acquires Aliada Therapeutics in $1.4bn deal
Oct 30, 2024 · Based in Boston, US, Aliada Therapeutics was founded in 2021 by Johnson & Johnson together with venture capital firm RA Capital Management. The company’s MODEL platform was originally created at Johnson & Johnson and licensed to Aliada when it was created.
UCB and Biogen: Phase 3 results for Dapirolizumab Pegol in …
Sep 24, 2024 · Belgian biopharma UCB and U.S. biotech Biogen today announced positive results from a Phase 3 study testing their drug candidate dapirolizumab pegol in people with systemic lupus erythematosus (SLE).
Help Centre - biopharma-reporter.com
When reading articles, you will be presented with messaging to create an account. Alternatively, you can click 'Register' in the top-right of your screen (this is accessible from the top-right user icon on a mobile device).